Cardiology in the Young

cambridge.org/cty

Utilising electroanatomic mapping during ablation in patients with CHD to reduce radiation exposure

Maryam Rahman[1], Jeremy P. Moore[2], John Papagiannis[3], Grace Smith[1], Chris Anderson[4], Kevin M. Shannon[2], Mansour Razminia[5], Volkan Tuzcu[6], Neil L. McNinch[7], Lisa M. Shauver[7] and John M. Clark[1]

[1]The Heart Center, Akron Children's Hospital, Akron, OH, USA; [2]Division of Pediatric Cardiology, Department of Pediatrics, UCLA Mattel Children's Hospital, Los Angeles, CA, USA; [3]Division of Cardiology, Children's Mercy Hospital, Kansas City, MO, USA; [4]Center for Congenital Heart Disease, Providence Sacred Heart Children's Hospital, Spokane, WA, USA; [5]Clinical Cardiac Electrophysiology, Amita Health Saint Joseph Hospital, Elgin, IL, USA; [6]Department of Pediatric Cardiology/Electrophysiology, Istanbul Medipol University Hospital, Istanbul, Turkey and [7]Rebecca D. Considine Research Institute, Akron Children's Hospital, Akron, OH, USA

Original Article

Cite this article: Rahman M, Moore JP, Papagiannis J, Smith G, Anderson C, Shannon KM, Razminia M, Tuzcu V, McNinch NL, Shauver LM, and Clark JM (2022) Utilising electroanatomic mapping during ablation in patients with CHD to reduce radiation exposure. *Cardiology in the Young* **32**: 1580–1584. doi: 10.1017/S1047951121004558

Received: 14 November 2020
Revised: 20 September 2021
Accepted: 24 October 2021
First published online: 18 November 2021

Keywords:
Three-dimensional mapping; catheter ablation; zero fluoroscopy; radiation; CHD; arrhythmia

Author for correspondence:
M. Rahman, DO, Department of Cardiology, The Heart Center, Akron Children's Hospital, One Perkins Square, Akron, OH 44308, USA.
Tel: 330-543-8521; Fax: 330-543-8208.
E-mail: mrahman@akronchildrens.org

Abstract

Background: Patients with CHD can be exposed to high levels of cumulative ionising radiation. Utilisation of electroanatomic mapping during catheter ablation leads to reduced radiation exposure in the general population but has not been well studied in patients with CHD. This study evaluated the radiation sparing benefit of using three-dimensional mapping in patients with CHD. *Methods:* Data were retrospectively collected from the Catheter Ablation with Reduction or Elimination of Fluoroscopy multi-institutional registry. Patients with CHD were selected. Those with previous ablations, concurrent diagnostic or interventional catheterisation and unknown arrhythmogenic foci were excluded. The control cohort was matched for operating physician, arrhythmia mechanism, arrhythmia location, weight and age. The procedure time, rate of fluoroscopy use, fluoroscopy time, procedural success, complications, and distribution of procedures per year were compared between the two groups. *Results:* Fifty-six patients with congenital heart disease and 56 matched patients without CHD were included. The mean total procedure time was significantly higher in patients with CHD (212.6 versus 169.5 minutes, $p = 0.003$). Their median total fluoroscopy time was 4.4 minutes (compared to 1.8 minutes), and their rate of fluoroscopy use was 23% (compared to 13%). The acute success and minor complication rates were similar and no major complications occurred. *Conclusions:* With the use of electroanatomic mapping during catheter ablation, fluoroscopy use can be reduced in patients with CHD. The majority of patients with CHD received zero fluoroscopy.

The presence of CHD imposes a lifetime risk of greater than average radiation exposure.[1–2] The cumulative radiation exposure from cardiac imaging and therapeutic interventions in CHD patients can be >20 mSv/year, which exceeds the recommended limit set by the International Commission on Radiological Protection for radiation workers.[1] This exposure to ionising radiation may be associated with an increased risk of cancer.[3–5] This is of clinical importance in patients with CHD who are now living longer and are more susceptible to the potential long-term adverse effects of radiation exposure.

Most of the radiation exposure in patients with CHD comes from cardiac catheterisation procedures.[1,6–7] This is due to the use of fluoroscopy during catheterisation. Three-dimensional mapping systems can be used during ablation procedures to reduce/eliminate the need for fluoroscopy and therefore exposure to ionising radiation. These systems use magnetic or electrical fields to create three-dimensional geometric maps of intracardiac structures and track the catheter position. They also create electrical activation wavefront maps which can identify the electrical circuits within the heart. The utilisation of three-dimensional mapping during cardiac ablation procedures decreases the use of fluoroscopy.[8–10]

The radiation reduction associated with the use of electroanatomic mapping has been extensively studied in normal cohorts of patients, however there are limited reports on it in patients with CHD. The purpose of this study was to evaluate the radiation sparing benefit of employing three-dimensional mapping during ablations of arrhythmias in patients with CHD and to compare it to outcomes in those without CHD, by controlling other variables, including operating physician, arrhythmia mechanism, arrhythmia location and patient size.

© The Author(s), 2021. Published by Cambridge University Press.

Table 1. Demographic data

	CHD						No CHD						
	N	Mean	SD	Median	Min	Max	N	Mean	SD	Median	Min	Max	Sign test p-value
Age (years)	56	17.5	13.7	14.4	0.03	59.8	56	12.6	7.1	13.2	0.1	46.4	0.081
Weight (kg)	56	52.0	26.7	54.6	3.6	128.8	56	51.0	24.8	55.0	3.8	124.8	1.000
Height (cm)	55	148.2	30.6	155.0	49.0	193.0	56	150.6	29.3	160.0	55.5	185.0	0.105




Figure 1. Distribution of procedures per year.

Materials and methods

The study was approved by the institutional review board of each participating centre.

Data were obtained retrospectively from the Catheter Ablation with Reduction or Elimination of Fluoroscopy registry, which is a multi-institutional research database tracking outcome of ablations in which three-dimensional mapping has been utilised in both children and adults from 2006 to present. This is a voluntary database and is not restricted to paediatric patients. At the time of data pull, there were 2146 patients enrolled in the database. Of those 2146 patients, 117 had CHD and were selected for inclusion. Patients who had previous ablations or concurrent diagnostic or interventional catheter procedures and those in whom the precise location of the arrhythmia was not reported were excluded. After those exclusions, 72 patients with CHD remained. From this group, patients with CHD were then matched to patients without CHD by sorting the database for the closest match based on the following criteria, in order: operating physician, arrhythmia mechanism, arrhythmia location, weight and age; 56 CHD patients were able to be matched.

All catheter ablation procedures were performed utilising one of the available three-dimensional electroanatomic mapping systems (EnSite, St. Jude Medical/Abbott or CARTO, Biosense Webster).

The following data were evaluated and compared between the two groups: total procedure time, rate of fluoroscopy use, total fluoroscopy time, acute procedural success, complications and distribution of procedures completed per year. Acute procedural success is categorised as complete success, partial success or failure. Complete success is defined as elimination of tachycardia and all evidence of the mechanism of that tachycardia. Partial success is defined as modification of the tachycardia or incomplete elimination of the underlying mechanism. Failure is defined as no change in the arrhythmia or substrate.

Statistical analysis

Examination of data included calculation of summary statistics and distributional assessments for continuous data and of frequencies and percentages for categorical data. The Sign test and Paired T-test were utilised to assess for potential differences in continuous variables by CHD status. McNemar's test and Test of symmetry were utilised for examination of potential associations of CHD status with categorical variables. Statistical analyses were completed using SAS 9.4/14.2©. All testing was two-tailed and evaluated at the type I error rate of $\alpha = 0.05$ level of statistical significance.

Results

Fifty-six patients with CHD and 56 matched patients without CHD who underwent a catheter ablation procedure using three-dimensional mapping from January, 2006 to December, 2019 were included in the study (Table 1). For the CHD group, the mean age was 17.5 ± 13.7 years and mean weight was 52.0 ± 26.7 kg. For the group with no CHD, the mean age was 12.6 ± 7.1 years and mean weight was 51.0 ± 24.8 kg. There was no statistically significant difference in weight ($p = 1.00$) or age ($p = 0.08$), although there was a trend toward older age in the CHD group. Figure 1 shows

https://doi.org/10.1017/S1047951121004558 Published online by Cambridge University Press

Table 2. Types of CHDs

CHD	N	Percentage
Unoperated simple CHD	17	30
Repaired two ventricle CHD – excluding TOF and arterial switch	15	27
Unoperated acyanotic CHD	12	21
Repaired tetralogy of Fallot (TOF) and TOF variants	5	9
Pre-Fontan palliated functional single ventricle	3	5
Transposition of the great arteries (TGA) following arterial switch	2	4
Unoperated cyanotic CHD	1	2
Fontan palliated functional single ventricle	1	2

Table 3. Types of arrhythmias

Arrhythmia	N	Percentage
AV-nodal reentrant tachycardia	22	39
Accessory pathway	20	36
Macro-reentrant atrial tachycardia	6	11
Ventricular arrhythmia	5	9
Focal atrial tachycardia	3	5

the distribution of procedures, per calendar year, comparing CHD and non-CHD patients.

The group with CHD (Table 2) consisted of patients with unoperated simple CHD (17/56, 30%), repaired two ventricle CHD – excluding tetralogy of Fallot and arterial switch (15/56, 27%), unoperated acyanotic CHD (12/56, 21%), repaired tetralogy of Fallot and tetralogy of Fallot variants (5/56, 9%), pre-Fontan palliated functional single ventricle (3/56, 5%), transposition of the great arteries following arterial switch (2/56, 4%), unoperated cyanotic CHD (1/56, 2%) and Fontan palliated functional single ventricle (1/56, 2%). The types of arrhythmias (Table 3) in each group included atrioventricular nodal reentrant tachycardia (22/56, 39%), accessory pathway (20/56, 36%), macro-reentrant atrial tachycardia (6/56, 11%), ventricular arrhythmia (5/56, 9%) and focal atrial tachycardia (3/56, 5%).

The procedure outcomes are shown in Table 4. In the group with CHD, the mean total procedure time was 212.6 ± 99.9 minutes (range 59.0–505.0 minutes); two patients had missing data for total procedure time. Fluoroscopy was used in 13/56 (23%) ablation procedures. Although fluoroscopy was used in 13 cases, fluoroscopy times were available for only 10. The other three cases reported fluoroscopy dose rather than time. The 10 procedures had a median total fluoroscopy time of 4.4 minutes (Interquartile range (IQR) 1.7–25.8 minutes). The 13 procedures that required fluoroscopy were performed on patients with the following CHDs: repaired two ventricle CHD (6/13, 46%), repaired tetralogy of Fallot and tetralogy of Fallot variants (3/13, 23%), unoperated simple CHD (3/13, 23%) and Fontan palliated single ventricle (1/13, 8%). The indications for fluoroscopy use included transseptal puncture, difficulty with three-dimensional mapping, confirming the location and other. Acute procedural success was achieved in 53/56 (95%) patients; 49 cases had complete success and 4 had partial success. There were no major complications, though there were minor complications in 5/56 (8.9%) patients. These five patients had the following CHDs: repaired two ventricle CHD (1/5, 20%), unoperated acyanotic CHD (3/5, 60%) and unoperated simple CHD (1/5, 20%). The minor complications included transient second-degree heart block (2/56, 3.6%), transient first-degree heart block (1/56, 1.8%), transient low blood pressure (1/56, 1.8%) and haematoma and edoema (1/56, 1.8%).

In the group without CHD, the mean total procedure time was 169.5 ± 69.8 minutes (range 54.0–328.0 minutes); one patient had missing data for total procedure time. Fluoroscopy was used in 7/56 (13%) ablation procedures. Although seven cases used fluoroscopy, fluoroscopy times were available for only five. The five procedures had a median total fluoroscopy time of 1.8 minutes (IQR 1.3–2.4 minutes). The indications for fluoroscopy use included transseptal puncture, confirming the location and other. There was acute procedural success in 54/55 (98%) patients; 51 had complete success and 3 had partial success. Final outcome was not reported in one patient. There were no major complications, though there were minor complications in 2/56 (3.6%) patients. The minor complications included transient complete heart block (1/56, 1.8%) and right external iliac pseudoaneurysm with haematoma (1/56, 1.8%).

Patients with CHD had a significantly higher mean total procedure time compared to patients without CHD (212.6 versus 169.5 minutes, $p = 0.003$). The majority of the procedures were performed using zero fluoroscopy. The rate of fluoroscopy use trended higher in patients with CHD compared to patients without CHD (13/56, 23% versus 7/56, 13%) but there was an insufficient number of patients to make statistical conclusions. For the procedures in which fluoroscopy was used, the median total fluoroscopy time trended higher in patients with CHD compared to non-CHD patients (4.4 versus 1.8 minutes), but there were too few patients to allow for statistical analysis. The acute success rates were similar in the two groups ($p = 0.80$). There was no significant difference in the complication rates between the two groups ($p = 0.26$).

Discussion

The use of an electroanatomic mapping system during ablation procedures has led to significant reduction in fluoroscopy use and therefore radiation exposure.[8–10] Although this has been demonstrated in patients with a normal heart, those with CHD have more complex anatomies and thus more challenges associated with ablations. The major finding of this study is that when three-dimensional mapping is utilised, radiation exposure in patients with CHD approached that of patients without CHD. With the use of three-dimensional mapping, both CHD and non-CHD patients have reduced radiation exposure compared to previously published reports.

Catheter ablation has evolved greatly over the years. When fluoroscopy was the only tool available to visualise the catheter position, radiation exposure was significant. In the Prospective Assessment after Pediatric Cardiac Ablation (PAPCA) multicentre study, Van Hare et al. prospectively evaluated 2761 paediatric patients with a structurally normal heart or trivial CHD who had supraventricular tachycardia due to an accessory pathway or atrioventricular nodal reentrant tachycardia and underwent radiofrequency ablation from 1999 to 2003. The authors reported a mean fluoroscopy time of 38.3 ± 1.5 minutes in their cohort.[11] While Van Hare's study evaluated patients with normal hearts, data regarding patients with CHD show even greater radiation exposure. Chiou et al. evaluated 600 patients with accessory

https://doi.org/10.1017/S1047951121004558 Published online by Cambridge University Press

Table 4. Procedural outcomes

Procedure outcomes	CHD						No CHD						p-value
	N	Mean	SD	Median	IQR	Min-Max	N	Mean	SD	Median	IQR	Min-Max	
Total procedure time (minutes)	54	212.6	99.9	179.0	143.0–271.0	59.0–505.0	55	169.5	69.8	154.0	114.0–226.0	54.0–328.0	0.003*
Total fluoroscopy time in all (minutes)	53	3.0	10.8	0.0	0.0–0.0	0.0–65.6	54	0.2	0.6	0.0	0.0–0.0	0.0–3.3	N/A
Total fluoroscopy time in cases with fluoroscopy use	10	15.6	21.3	4.4	1.7–25.8	0.03–65.6	5	1.9	1.1	1.8	1.3–2.4	0.5–3.3	N/A

*Paired T-test.

pathway-mediated tachycardia and 455 with atrioventricular nodal reentrant tachycardia who underwent radiofrequency catheter ablation from 1990 to 1994. Twenty-one patients had CHD. They reported radiation times of 102 ± 27 versus 35 ± 23 minutes for accessory pathway ablation and 62 ± 23 versus 20 ± 11 minutes for atrioventricular nodal reentrant tachycardia ablation in patients with CHD versus patients with no CHD, respectively.[12] The radiation times in patients with CHD are much higher than those reported by Van Hare et al in patients with a normal heart or trivial CHD. With the use of fluoroscopy alone, the long fluoroscopy times resulted in significant radiation exposure during catheter ablations.

In the era of three-dimensional mapping, radiation exposure has markedly diminished. This is true for both patients with normal hearts and those with CHD. Morka et al prospectively evaluated 1280 adult patients with supraventricular tachycardia (174 with structural heart disease, 1106 with no structural heart disease) who underwent ablations using a three-dimensional mapping system (Ensite Velocity) from 2012 to 2017. The majority of those with structural heart disease had acquired disease, with very few congenital defects. The authors reported similar total fluoroscopy times (5.05 ± 5.13 minutes in structural heart disease versus 5.59 ± 7.45 minutes in no structural heart disease), number of applications and radiation doses, in the two groups.[13] There are two other published studies which evaluated the use of electroanatomic mapping during ablations of arrhythmias in patients with CHD and its effect on radiation exposure. Cano et al evaluated 55 adult patients with CHD (simple, moderate and complex) who underwent ablations via a minimally fluoroscopic approach using the Carto Univu Image Integration Module (IIM) from 2014 to 2017. The authors reported very low levels of radiation exposure using the Image Integration Module. The mean total fluoroscopy times were extremely low (1.94 ± 3.68 minutes for simple CHD, 0.36 ± 0.79 minutes for moderate CHD, 2.21 ± 3.79 minutes for complex CHD) in comparison to previously published data (18.5 ± 10 minutes for simple CHD, 25 ± 14.8 minutes for moderate CHD, 25.6 ± 12.9 minutes for complex CHD).[14] The other study by Clark et al retrospectively evaluated outcomes of ablation procedures with and without the use of three-dimensional mapping (Carto 3) in three paediatric and adult groups (normal heart, CHD, those requiring transseptal access) between 2012 and 2015. The mean fluoroscopy times decreased significantly with the use of three-dimensional mapping in all three groups, including those with CHD (16.2 ± 16.2 minutes decreased to 4.2 ± 8.4 minutes in the normal heart group; 15.1 ± 16.0 minutes decreased to 3.2 ± 3.4 minutes in the CHD group; 35.1 ± 29.0 minutes decreased to 12.1 ± 15.1 minutes in the transseptal group).[15] The use of three-dimensional mapping has resulted in reduced fluoroscopy times and therefore radiation exposure during catheter ablations.

The findings in the current study are consistent with the limited published data available. Our study includes data from a multi-institutional database and includes both paediatric and adult patients, complex arrhythmias and complex CHD. Despite including complex atrial and ventricular arrhythmias, the fluoroscopy times for patients with a structurally normal heart are minimal (88% received no fluoroscopy; median fluoroscopy time for those that received fluoroscopy was 1.8 minutes). The fluoroscopy times for the group with CHD approach those of patients without CHD, although they are still slightly greater (77% of CHD patients received no fluoroscopy; median fluoroscopy time for those that received fluoroscopy was 4.4 minutes). Despite including more complex atrial and ventricular arrhythmias, and a broad range of CHD, the median fluoroscopy time was still only 4.4 minutes when three-dimensional mapping was used. Patients with CHD and those without CHD both experienced reduction in radiation exposure with the use of three-dimensional mapping.

Our study also demonstrated that patients with CHD had a higher total procedure time and rate of fluoroscopy use compared to patients with no CHD. This is not surprising given that catheter ablation procedures are more technically challenging to perform on patients with CHD. This may be related to their complex anatomical structures, increased risk of complex arrhythmias, as well as diagnostic and mapping challenges. Arrhythmias can occur due to coexisting abnormalities of the conduction system, haemodynamic effects on the heart structure and/or post-surgical changes.[16] Patients with CHD can have different chamber dimensions, multiple loop circuits and increased ablation lines.[17] These complexities can prolong the duration of the procedure and require the use of fluoroscopy. Similar to our findings, Chiou et al reported that procedure times were longer (3.9 ± 0.7 versus 2.4 ± 1.3 hours for accessory pathway ablation and 3 ± 0.7 versus 2.5 ± 0.8 hours for atrioventricular nodal reentrant tachycardia ablation) in CHD patients compared to patients with structurally normal hearts.[12] Morka et al also reported a higher rate of fluoroscopy use in patients with structural heart disease as compared to patients with no structural heart disease (13.2% in structural heart disease and 7.8% in no structural heart disease; $p = 0.02$). However, they reported similar total procedure times in the two groups (51.2 ± 26.9 minutes in structural heart disease and 49.9 ± 25.2 minutes in no structural heart disease; $p = 0.55$).[13] One possible explanation for the discrepancy between studies may be the lack of inclusion of patients with severe CHD in Morka's study, which

https://doi.org/10.1017/S1047951121004558 Published online by Cambridge University Press

could lead to an underestimation of the total procedure time in the CHD group. The study by Clark et al reported higher procedure times in patients with CHD compared to patients with a normal heart, although it did demonstrate a decrease in procedure times with the use of electroanatomic mapping in all groups (155.1 ± 76.6 minutes before three-dimensional mapping and 140.0 ± 84.9 minutes after three-dimensional mapping in normal hearts; 168.9 ± 88.6 minutes before three-dimensional mapping and 163.9 ± 101.6 minutes after three-dimensional mapping in CHD).[15] Although patients with CHD have a higher total procedure time and rate of fluoroscopy use, they have overall reduced fluoroscopy times with the use of three-dimensional mapping versus fluoroscopy alone.

A potential factor that may have influenced fluoroscopy use is the time period in which the procedures were performed. If one group had procedures performed at a relatively earlier time period, the skill level of the operator may have influenced the use and duration of fluoroscopy and possibly led to higher fluoroscopy times. However, our data demonstrated that neither group had the majority of their procedures performed at an earlier time period.

Three-dimensional mapping systems have reduced fluoroscopy exposure in CHD patients to amounts nearly matching patients with structurally normal hearts. In this study, 77% of patients with CHD received zero fluoroscopy, while 88% of patients with normal hearts achieved that benchmark. On average, patients with CHD received only 2.6 minutes more fluoroscopy than patients with normal hearts. This is the first multi-institutional study to compare the radiation exposure associated with the use of electroanatomic mapping in patients with CHD to patients with structurally normal hearts.

Limitations

This was a retrospective study with some missing data noted. Long-term success was not evaluated as we focused only on acute findings. In addition, the sample size was relatively small and raises concern for potential sampling bias. Given that we used a voluntary database, there is no means of assessing how many potential patients were not enrolled. However, the small sample size is also partly due to the fact that we ensured that the study group was closely matched to the cohort group. Specifically, we thought it was important to match the groups by operating physician, given that the physicians' skill can greatly affect the procedure time and fluoroscopy time.

Conclusion

Using current technology, fluoroscopy can be reduced or eliminated in patients with CHD and those without CHD. In this study, 77% of the CHD patients had their procedures performed without using fluoroscopy, compared to 88% of the non-CHD patients. While there is a trend toward increased use of fluoroscopy and longer fluoroscopy times in the CHD group, there is insufficient number of patients to make statistical conclusions. This approach yielded similar acute success and minor complication rates and no major complications in the two groups. The findings in this study are of clinical importance since patients with congenital heart disease can be exposed to high levels of cumulative ionising radiation. Efforts to further reduce this exposure should be undertaken. In future studies, it will be useful to evaluate the effect of different three-dimensional mapping systems (Ensite versus Carto) on fluoroscopy times and radiation exposure.

Acknowledgements. We would like to thank the Rebecca D. Considine Research Institute for their administrative support.

Financial support. This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflicts of interest. Dr Razminia is a consultant for Abbott. The other authors have no conflicts of interest to declare.

References

1. Glatz AC, Purrington KS, Klinger A, et al. Cumulative exposure to medical radiation for children requiring surgery for congenital heart disease. J Pediatr 2014; 164: 789–794.
2. Beauséjour Ladouceur V, Lawler PR, Gurvitz M, et al. Exposure to low-dose ionizing radiation from cardiac procedures in patients with congenital heart disease: 15-year data from a population-based longitudinal cohort. Circulation 2016; 133: 12–20.
3. Danieli C, Cohen S, Liu A, et al. Flexible modeling of the association between cumulative exposure to low-dose ionizing radiation from cardiac procedures and risk of cancer in adults with congenital heart disease. Am J Epidemiol 2019; 188: 1552–1562.
4. Journy N, Dreuil S, Rage E, et al. Projected future cancer risks in children treated with fluoroscopy-guided cardiac catheterization procedures. Circ Cardiovasc Interv 2018; 11: e006765.
5. Andreassi MG. Radiation risk from pediatric cardiac catheterization: friendly fire on children with congenital heart disease. Circulation 2009; 120: 1847–1849.
6. Walsh MA, Noga M, Rutledge J. Cumulative radiation exposure in pediatric patients with congenital heart disease. Pediatr Cardiol 2015; 36: 289–294.
7. Downing TE, McDonnell A, Zhu X, et al. Cumulative medical radiation exposure throughout staged palliation of single ventricle congenital heart disease. Pediatr Cardiol 2015; 36: 190–195.
8. Clark J, Bockoven JR, Lane J, Patel CR, Smith G. Use of three-dimensional catheter guidance and trans-esophageal echocardiography to eliminate fluoroscopy in catheter ablation of left-sided accessory pathways. Pacing Clin Electrophysiol 2008; 31: 283–289.
9. Smith G, Clark JM. Elimination of fluoroscopy use in a pediatric electrophysiology laboratory utilizing three-dimensional mapping. Pacing Clin Electrophysiol 2007; 30: 510–518.
10. Papagiannis J, Avramidis D, Alexopoulos C, Kirvassilis G. Radiofrequency ablation of accessory pathways in children and congenital heart disease patients: impact of a nonfluoroscopic navigation system. Pacing Clin Electrophysiol 2011; 34: 1288–1396.
11. Van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol 2004; 15: 759–770.
12. Chiou CW, Chen SA, Chiang CE, et al. Radiofrequency catheter ablation of paroxysmal supraventricular tachycardia in patients with congenital heart disease. Int J Cardiol 1995; 50: 143–151.
13. Morka A, Śledź J, Deutsch K, et al. Feasibility and performance of catheter ablation with zero-fluoroscopy approach for regular supraventricular tachycardia in patients with structural and/or congenital heart disease. Medicine 2019; 98: 41.
14. Cano Ó., Saurí A, Plaza D, et al. Evaluation of a near-zero fluoroscopic approach for catheter ablation in patients with congenital heart disease. J Interv Card Electrophysiol 2019; 56: 259–269.
15. Clark BC, Sumihara K, McCarter R, Berul CI, Moak JP. Getting to zero: impact of electroanatomic mapping on fluoroscopy use in pediatric catheter ablation. J Interv Card Electrophysiol 2016; 46: 183–189.
16. Szili-Torok T, Kornyei L, Jordaens LJ. Transcatheter ablation of arrhythmias associated with congenital heart disease. J Interv Card Electrophysiol 2008; 22: 161–166.
17. Kean AC, LaPage MJ, Yu S, Dick M II, Bradley DJ. Patient and procedural correlates of fluoroscopy use during catheter ablation in the pediatric and congenital electrophysiology lab. Congenit Heart Dis 2015; 10: 281–287.

https://doi.org/10.1017/S1047951121004558 Published online by Cambridge University Press